"uuid:ID","rationale","description","name","instanceType","id","label"
"8b1b993a-2148-4e18-ab44-ee38457e3210","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","Study Design 1","StudyDesign","StudyDesign_1",""
